BEXMAB Survival Data Remain Subgroup-Dependent

Company Faron Pharmaceuticals Event Type Clinical Trial Results (Phase 1/2) Modality Humanized antibody (anti-Clever-1) plus hypomethylating agent Asset Bexmarilimab + azacitidine (BEXMAB) Target Clever-1 (immunosuppressive macrophage receptor) Disease Area Higher-risk myelodysplastic syndrome (MDS), frontline/treatment-naïve Summary Faron Pharmaceuticals reported the first overall-survival cut from 21 treatment-naïve…